NCT04021082View on ClinicalTrials.gov

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 15, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

June 1, 2023

Conditions
Peripheral T-Cell Lymphoma (PTCL NOS)Nodal Lymphomas of T Follicular Helper (TFH)Follicular T-cell Lymphoma (FTCL)AITLALCLHSTCLEATL I,IIMEITL, EATL Type IINasal Lymphoma
Interventions
DRUG

Cerdulatinib

Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT04021082 - CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | Biotech Hunter | Biotech Hunter